Skip to main content
Year archive

Xbrane Biopharma — 2023 filings

All 63 regulatory filings released by Xbrane Biopharma (XBRANE) in 2023, sourced directly from the official regulator.

63 Filings
2023 Period
2023 filings (63)
Filing Released Lang
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-29 English
XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES
AGM Information
2023-12-20 English
XBRANE BIOPHARMA MEDDELAR FÖRÄNDRING AV VALBEREDNING
Board/Management Information
2023-12-20 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-13 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-11 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-08 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-08 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-07 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-06 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-04 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-12-04 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-30 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report 9M 2023
2023-11-30 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-27 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements
2023-11-24 English
Xbrane Biopharma is focusing the development portfolio and introducing a cost-savings scheme
Management Reports
2023-11-23 English
Xbrane Biopharma fokuserar utvecklingsportföljen och inför ett kostnadsbesparingsprogram
Management Reports
2023-11-23 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-20 English
Xbrane Biopharma AB ("Xbrane" or the "Company") announces changes to the number of shares and votes in the Company.
Declaration of Voting Results & Voting Rights Announcements
2023-10-31 English
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") meddelar om förändring av antalet aktier och röster i Bolaget.
Declaration of Voting Results & Voting Rights Announcements
2023-10-31 Swedish
Xbrane Biopharma presenterar Valberedning
Board/Management Information
2023-10-18 Swedish
Xbrane Biopharma presents Nomination Committee
Board/Management Information
2023-10-18 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-10-18 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-10-13 English
Change of number of shares and votes in Xbrane
Share Issue/Capital Change
2023-09-30 English
Förändrat antal aktier och röster i Xbrane
Share Issue/Capital Change
2023-09-30 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification
2023-09-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-08-31 English
Interim / Quarterly Report 2023
Interim / Quarterly Report H2 2023
2023-08-29 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report H1 2023
2023-08-29 English
XBRANE UPDATES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW ON AN MONTHLY BASIS BEFORE END OF FIRST QUARTER 2025
Management Reports
2023-08-29 English
XBRANE UPPDATERAR SIN AMBITION ATT GENERERA POSITIVT OPERATIVT KASSAFLÖDE PÅ MÅNADSBASIS INNAN SLUTET AV FÖRSTA KVARTALET 2025
Earnings Release FY 2023
2023-08-29 Swedish
STADA and Xbrane weigh options for ranibizumab biosimilar candidate
Regulatory Filings
2023-07-25 English
STADA och Xbrane överväger alternativ, inklusive utlicensiering av sin ranibizumab biosimilarkandidat
Regulatory Filings
2023-07-25 Swedish
Xbrane meddelar idag att bolagets ansökan till FDA avseende en biosimilarkandidat till Lucentis® (ranibizumab) validerats av myndigheten
Regulatory Filings
2023-06-21 Swedish
Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate
Regulatory Filings
2023-06-21 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-06-02 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-31 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-31 English
Change of number of shares and votes in Xbrane
Declaration of Voting Results & Voting Rights Announcements
2023-05-31 English
Förändrat antal aktier och röster i Xbrane
Declaration of Voting Results & Voting Rights Announcements
2023-05-31 Swedish
STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany
Regulatory Filings
2023-05-26 English
STADA och Xbrane lanserar Ximluci® som ranibizumab biosimilar i Tyskland
Regulatory Filings
2023-05-26 Swedish
Xbrane has carried out a directed share issue and an issue of convertible bonds raising gross proceeds of approximately SEK 350 million
Share Issue/Capital Change
2023-05-23 English
Xbrane har genomfört en riktad nyemission samt en emission av konvertibla obligationer och tillförs därigenom en bruttolikvid om cirka 350 miljoner kronor
Share Issue/Capital Change
2023-05-23 Swedish
Xbrane announces its intention to carry out a directed share issue and an issue of convertible bonds totaling approximately SEK 325 million in financing
Capital/Financing Update
2023-05-22 English
Xbrane offentliggör avsikt att genomföra en riktad nyemission och en emission av konvertibla obligationer om totalt cirka 325 miljoner kronor i finansiering
Share Issue/Capital Change
2023-05-22 Swedish
Announcement from Xbrane Biopharma's annual general meeting
AGM Information
2023-05-04 English
Kommuniké från årsstämman i Xbrane Biopharma
AGM Information
2023-05-04 Swedish
STADA och Xbrane levererar Ximluci® (ranibizumab) i England under kontrakt med NHS
Regulatory Filings
2023-04-25 Swedish
STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract
Regulatory Filings
2023-04-25 English
XBRANE submits BLA for ranibizumab biosimilar candidate to FDA
Report Publication Announcement
2023-04-24 English
XBRANE skickar in ansökan om marknadsgodkännande för sin ranibizumab biosimilarkandidat till FDA
Regulatory Filings
2023-04-24 Swedish
Kallelse till årsstämma i Xbrane Biopharma AB
AGM Information
2023-04-03 Swedish
Notice of annual general meeting in Xbrane Biopharma AB
AGM Information
2023-04-03 English
STADA och Xbrane lanserar ranibizumab för att öka tillgängligheten för patienter i Europa
Regulatory Filings
2023-04-03 Swedish
STADA and Xbrane launch ranibizumab to support patient access in Europe
Regulatory Filings
2023-04-03 English
Annual Report 2022
Annual Report FY 2022
2023-03-31 Swedish
Annual Report 2022
Annual Report FY 2022
2023-03-31 Swedish
Earnings Release 2022
Earnings Release Q4 2022
2023-02-17 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report FY 2022
2023-02-17 English
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
Regulatory Filings
2023-01-17 English
STADA och Xbrane erhåller godkännande i Storbritannien för Ximluci® (ranibizumab) biosimilar till referensläkemedlet Lucentis®
Regulatory Filings
2023-01-17 Swedish